Table 2.
Characteristics of patients filing only one or filing more than one MTX prescription: predictors of filing only one or filing two or more MTX prescriptions.
| Variables | One MTX prescription | Two or more MTX prescriptions | P value (Pearson chi-square test, 2-sided) |
|---|---|---|---|
| ≤50 years | 679 (15%) | 3,849 (85%) | <0.001 |
| 51–60 years | 648 (15%) | 3,672 (85%) | |
| 61–70 years | 631 (13%) | 4,223 (87%) | |
| >70 years | 950 (19%) | 4,053 (81%) | |
| Men | 784 (15%) | 4,447 (85%) | 0.089 |
| Women | 2,161 (16%) | 11,350 (84%) | |
| No prior use of prednisolone/prednisone | 1,053 (15%) | 6,206 (85%) | 0.002 |
| Prior use of prednisolone/prednisone | 1,853 (16%) | 9,591 (84%) | |
| No AMI | 2,741 (15%) | 15,188 (85%) | <0.001 |
| AMI | 165 (21%) | 609 (79%) | |
| No cerebrovascular disease | 2,697 (15%) | 15,015 (85%) | <0.001 |
| Cerebrovascular disease | 209 (21%) | 782 (79%) | |
| No dementia | 2,884 (15%) | 15,739 (85%) | 0.003 |
| Dementia | 22 (27%) | 58 (73%) | |
| No complications to T1D | 2,860 (15%) | 15,660 (85%) | <0.001 |
| Complications to T1D | 46 (25%) | 137 (75%) | |
| No complications to T2D | 2,834 (15%) | 15,590 (85%) | <0.001 |
| Complications to T2D | 72 (26%) | 207 (74%) | |
| No T1D | 2,830 (15%) | 15,551 (85%) | <0.001 |
| T1D | 76 (24%) | 246 (76%) | |
| No T2D | 2,751 (15%) | 15,218 (85%) | <0.001 |
| T2D | 155 (21%) | 579 (79%) | |
| No hemiplegia | 2,898 (15%) | 15,775 (85%) | 0.092 |
| Hemiplegia | 8 (27%) | 22 (73%) | |
| No heart failure | 2,735 (15%) | 15,281 (85%) | <0.001 |
| Heart failure | 171 (25%) | 516 (75%) | |
| No peripheral vascular disease | 2,741 (15%) | 15,268 (85%) | <0.001 |
| Peripheral vascular disease | 165 (24%) | 529 (76%) | |
| No chronic lung disease | 2,553 (15%) | 14,588 (85%) | <0.001 |
| Chronic lung disease | 353 (23%) | 1,209 (77%) | |
| No leukemia | 2,901 (15%) | 15,773 (85%) | 0.800 |
| Leukemia | 5 (17%) | 24 (83%) | |
| No lymphoma | 2,886 (15%) | 15,718 (85%) | 0.199 |
| Lymphoma | 20 (20%) | 79 (80%) | |
| No metastases | 2,880 (15%) | 15,725 (85%) | 0.003 |
| Metastases | 26 (26%) | 72 (74%) | |
| No mild liver disease | 2,852 (15%) | 15,647 (85%) | <0.001 |
| Mild liver disease | 54 (26%) | 150 (74%) | |
| No moderate to severe liver disease | 2,903 (15%) | 15,771 (85%) | 0.440 |
| Moderate to severe liver disease | 3 (10%) | 26 (90%) | |
| No kidney disease | 2,816 (15%) | 15,560 (85%) | <0.001 |
| Kidney disease | 90 (27%) | 237 (73%) | |
| No cancer | 2,813 (15%) | 15,414 (85%) | 0.015 |
| Cancer | 93 (19%) | 383 (81%) | |
| No ulcer | 2,664 (15%) | 14,832 (85%) | <0.001 |
| Ulcer | 242 (20%) | 965 (80%) |